Glycemic effects and safety of L-glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Samocha Bonet, Dorit ^a,b   Chisholm, Donald J ^a,b   Gribble, Fiona M ^c   Coster, Adelle C F ^b   Carpenter, Kevin H ^d   Jones, Graham R D ^b,e   Holst, Jens J ^f   Greenfield, Jerry R ^a,b,e  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF SYDNEY   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; ELECTROLYTE; FRUCTOSAMINE; GLUCOSE; GLUTAMINE; HEMOGLOBIN; HEMOGLOBIN A1C; METFORMIN; PLACEBO; SITAGLIPTIN; UREA; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES CONTROL; DIABETIC PATIENT; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ELECTROLYTE BLOOD LEVEL; ERYTHROCYTE; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HUMAN; HUMAN CELL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UREA BLOOD LEVEL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PLASMA VOLUME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLUTAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PLASMA VOLUME; SITAGLIPTIN PHOSPHATE; TREATMENT OUTCOME;

EID: 84913534504     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113366     Document Type: Article

References (18)

1. Drucker DJ (2006) The biology of incretin hormones. Cell Metabolism 3: 153-165.
2. Holst JJ, Vilsboll T, Deacon CF (2009) The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297: 127-136.
3. Nauck MA, Baller B, Meier JJ (2004) Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 53 Suppl 3: S190-196.
4. Thomas E, Habener JF (2010) Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trend Endocrinol Metab 21: 59-68.
5. Reimann F, Williams L, da Silva Xavier G, Rutter GA, Gribble FM (2004) Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells. Diabetologia 47: 1592-1601.
6. Tolhurst G, Zheng Y, Parker HE, Habib AM, Reimann F, et al. (2011) Glutamine triggers and potentiates glucagon-like peptide-1 secretion by raising cytosolic Ca2 + and cAMP. Endocrinology 152: 405-413.
7. Greenfield JR, Farooqi IS, Keogh JM, Henning E, Habib AM, et al. (2009) Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Am J Clin Nutr 89: 106-113.
8. Samocha-Bonet D, Wong O, Synnott EL, Piyaratna N, Douglas A, et al. (2011) Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients. J Nutr 141: 1233-1238.
9. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43: 535-539.
10. Cohen RM, Franco RS, Khera PK, Smith EP, Lindsell CJ, et al. (2008) Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood 112: 4284-4291.
11. Solis-Herrera C, Triplitt C, Garduno-Garcia JdJ, Adams J, DeFronzo RA, et al. (2013) Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes: A doubletracer study. Diabetes Care 36: 2756-2762.
12. Novak F, Heyland DK, Avenell A, Drover JW, Su X (2002) Glutamine supplementation in serious illness: a systematic review of the evidence. Crit Care Med 30: 2022-2029.
13. Heyland D, Drover J, Dhaliwal R (2006) Does the addition of glutamine to enteral feeds affect patient mortality? Crit Care Med 34: 2031-2032; author reply 2032.
14. Andrews PJD, Avenell A, Noble DW, Campbell MK, Croal BL, et al. (2011) Randomised trial of glutamine, selenium, or both, to supplement parenteral nutrition for critically ill patients. Br Med J 342
15. Menge BA, Schrader H, Ritter PR, Ellrichmann M, Uhl W, et al. (2010) Selective amino acid deficiency in patients with impaired glucose tolerance and type 2 diabetes. Regul Pept 160: 75-80.
16. Gleeson M (2008) Dosing and Efficacy of Glutamine Supplementation in Human Exercise and Sport Training. J Nutr 138: 2045S-2049S.
17. Galera SC, Fechine F, Teixeira MJ, Branco Coelho ZC, de Vasconcelos RC, et al. (2010) The safety of oral use of l-glutamine in middle-aged and elderly individuals. Nutrition 26: 375-381.
18. House JD, Pencharz PB, Ball RO (1994) Glutamine Supplementation to Total Parenteral Nutrition Promotes Extracellular Fluid Expansion in Piglets. J Nutr 124: 396-405.